These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 7029967)

  • 21. Characterization of Serratia marcescens isolates from subgingival biofilm, extraoral infections and environment by prodigiosin production, serotyping, and genotyping.
    Barbosa FC; Irino K; Carbonell GV; Mayer MP
    Oral Microbiol Immunol; 2006 Feb; 21(1):53-60. PubMed ID: 16390342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virulence of nosocomial isolates of Serratia marcescens for NMRI mice: correlation with O-antigens O6 and O14.
    Traub WH
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Jul; 252(3):360-9. PubMed ID: 6182709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different O and K serotype distributions among clinical and environmental strains of Serratia marcescens.
    Aucken HM; Pitt TL
    J Med Microbiol; 1998 Dec; 47(12):1097-104. PubMed ID: 9856646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Epidemiological evaluation of Serratia marcescens clinical isolates in a general hospital during the past three years: appearance of O-antigens O2 and O14].
    Marumo K; Nakamura Y; Sakurai C
    Rinsho Byori; 1998 Jul; 46(7):728-33. PubMed ID: 9721543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid identification of Serratia marcescens by coagglutination.
    Roig JM; Dorronsoro I; Diaz R
    J Clin Microbiol; 1983 Sep; 18(3):741-2. PubMed ID: 6195186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase variation in the genus Serratia.
    Young VM; Moody MR; Morris MJ
    J Med Microbiol; 1980 May; 13(2):341-3. PubMed ID: 6991701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opsonization requirements of Serratia marcescens.
    Traub WH
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Nov; 253(2):204-24. PubMed ID: 6187137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunochemical characterization of two new O serotypes of Serratia marcescens (O27 and O28).
    Aucken HM; Wilkinson SG; Pitt TL
    FEMS Microbiol Lett; 1996 Apr; 138(1):77-82. PubMed ID: 8674974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure of a neutral glycan from the lipopolysaccharides of reference strains for Serratia marcescens serogroups O2 and O3.
    Oxley D; Wilkinson SG
    FEMS Microbiol Lett; 1992 Dec; 78(2-3):209-12. PubMed ID: 1283379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative biotyping, bacteriocin typing, and serogrouping (O-antigens) of Serratia liquefaciens.
    Traub WH
    Zentralbl Bakteriol; 1991 Jun; 275(2):200-10. PubMed ID: 1718303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Re-evaluation of the serotypes of Serratia marcescens and separation into two schemes based on lipopolysaccharide (O) and capsular polysaccharide (K) antigens.
    Aucken HM; Wilkinson SG; Pitt TL
    Microbiology (Reading); 1998 Mar; 144 ( Pt 3)():639-653. PubMed ID: 9534235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure of the O-specific galactan from the lipopolysaccharide of the reference strain for Serratia marcescens serogroup O24.
    Oxley D; Wilkinson SG
    Carbohydr Res; 1989 Dec; 195(1):117-22. PubMed ID: 2699831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of O-antigen in susceptibility of Serratia marcescens to non-immune serum.
    Palomar J; Montilla R; Fusté MC; Viñas M
    Microbios; 1993; 76(308):189-96. PubMed ID: 8302200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human serum bactericidal activity against Serratia marcescens: failure of human, "natural," specific anti-O IgG antibodies to enhance serum bactericidal activity.
    Traub WH
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1981; 250(1-2):84-91. PubMed ID: 7032154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure of a glucorhamnan from the lipopolysaccharide of Serratia marcescens strain S1254.
    Oxley D; Wilkinson SG
    Carbohydr Res; 1991 Jan; 209():319-22. PubMed ID: 1709820
    [No Abstract]   [Full Text] [Related]  

  • 36. Failure of a commercial, intravenously applicable IgG F (ab)2 preparation (Gamma-Venin) to enhance human serum bactericidal activity against Serratia marcescens.
    Traub WH
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1981; 249(4):504-11. PubMed ID: 6171949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on group A (phage tail) bacteriocins of Serratia marcescens. V. Serological characterization of subgroup I and II bacteriocins.
    Traub WH; Kleber I
    Zentralbl Bakteriol Orig A; 1976 May; 234(4):521-7. PubMed ID: 779357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [O-serotypes, biotypes and antimicrobial susceptibilities of Serratia marcescens isolates from clinical specimens: 4th report].
    Marumo K; Nakamura Y; Fukuda S
    Rinsho Byori; 1995 Nov; 43(11):1140-6. PubMed ID: 8551678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibiotic resistance and putative virulence factors of Serratia marcescens with respect to O and K serotypes.
    Aucken HM; Pitt TL
    J Med Microbiol; 1998 Dec; 47(12):1105-13. PubMed ID: 9856647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined serotyping and biotyping of Serratia marcescens.
    Rubin SJ; Brock S; Chamberland M; Lyons RW
    J Clin Microbiol; 1976 Jun; 3(6):582-5. PubMed ID: 780372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.